回顾性研究宫颈癌患者^(18)F-FDGPET/CT显像发现甲状腺偶发瘤的特点

Retrospective Study of the Characteristics of Incidental Thyroid Tumors Detected During^(18)F-FDG PET/CT Imaging in Patients with Cervical Cancer

目的回顾性研究^(18)F-FDGPET/CT用于宫颈癌患者治疗前分期及治疗后疗效评估时检测到甲状腺偶发瘤的特点。方法我们回顾性的统计了从2015年至2021年在我院接受^(18)F-FDGPET/CT检查进行宫颈癌治疗前分期及治疗后疗效评估患者的电子病历。其中甲状腺有显像剂摄取增高征象且以前未诊断过甲状腺相关疾病的报告纳入研究。最后统计纳入研究者的甲状腺穿刺活检、手术及超声结果。结果在接受^(18)F-FDGPET/CT检查的1283例宫颈癌患者中,共有152例患者出现甲状腺显像剂摄取增高征象,其中90例患者甲状腺糖代谢呈弥漫性增高,62例患者呈局灶性增高。甲状腺FDG弥漫性及局灶性摄取的SUVmax值之间无统计学差异。最后发现在局灶性增高的患者中有10例被证实是甲状腺恶性肿瘤且病理类型均为甲状腺乳头状癌。在这10例患者中有8例为宫颈鳞状细胞癌,2例患者未查到相应资料。结论宫颈癌患者在进行^(18)F-FDGPET/CT治疗前分期及治疗后疗效评估时,可发现甲状腺糖代谢增高征象,其中某些局灶性病灶具有很高的甲状腺恶性肿瘤的风险,以甲状腺乳头状癌多见,尤其是宫颈鳞状细胞癌的患者。因此需要完善甲状腺相关检查进一步明确。

Objective To retrospectively study the characteristics ofthyroid incidentals detected by pre-treatment and post-treatment^(18)F-FDG PET/CT in patients with cervical cancer.Methods We retrospectively analyzed the electronic medical records of patients with cervical cancer who received pre-treatment and post-treatment^(18)F-FDG PET/CT examination at our hospital from 2015 to 2021.Among them,reports of thyroid with signs of increased imaging agent uptake and no previous diagnosis of thyroidrelated disease were included in the study.Finally,the thyroid puncture biopsy,surgical and ultrasound results of those included in the study were counted.Results Of 1283 patients with cervical cancer who underwent^(18)F-FDG PET/CT,152 patients showed thyroid FDG uptake,including 90 patients with diffuse uptake and 62 patients with focal uptake.There was no statistical difference between diffuse and focal uptake SUVmax values of thyroid FDG.Finally,10 of 62 patients with focal uptake were diagnosed thyroid malignancies and all had papillary thyroid carcinoma as the pathological type.Of these 10 patients,8 had cervical squamous cell carcinoma and 2 had no relevant data.Conclusion thyroid increased FDG uptake can be detected by pre-treatment and post-treatment^(18)F-FDG PET/CT in patients with cervical cancer,where certain focal uptake have a high risk of thyroid malignancy,most commonly papillary thyroid carcinoma,especially in patients with cervical squamous cell carcinoma.Therefore,thyroid-related tests need to be completed for further clarification.